Pub Date : 2022-11-02DOI: 10.26420/thrombhaemostres.2022.1084
Özkan G, Bayrakçi N, Mutlu Lc, Erdem I, Tuna N, D. m., Yildirim I, Erdal B, çelikkol A, Y. a, Güzel S
Aim: Thromboembolic complications are an important cause of mortality and morbidity in coronavirus disease 2019 (COVID-19) patients. The purpose of this study was to compare levels of the platelet activation markers soluble CD40 ligand (sCD 40L) and signal peptide-CUB-EGF domain-containing protein 1 (SCUBE 1) and hematological parameters between laboratory-confirmed and clinically diagnosed COVID-19 patients. No previous studies have investigated levels of these markers in laboratory-confirmed and clinically diagnosed COVID-19 patients. Material and Method: Fifty-one laboratory-confirmed and clinically diagnosed COVID-19 patients with no exclusion criteria were enrolled in the study. Blood specimens were collected for SCUBE1, sCD40 L, and hematological and biochemical parameter measurement. These parameters from laboratoryconfirmed and clinically diagnosed COVID-19 patients were then compared. Results: SCUBE1 and sCD40L levels were significantly higher in the laboratory-confirmed group compared to the clinically diagnosed group (p<0.05 and p =0.005, respectively). Time elapsing between onset of symptoms and presentation to hospital was significantly shorter in the laboratory-confirmed group, while rates of contact with COVID-19 patients were significantly higher (p <0.001 and p <0.005, respectively). SCUBE 1 levels were significantly negatively correlated with ferritin and C-reactive protein (CRP) (p< 0.05, r= - 0.322 and p< 0.05, r= - 0.351, respectively). Conclusion: This study shows, for the first time in the literature, that levels of the platelet activation markers SCUBE1 and sCD40L are significantly higher in laboratory-confirmed COVID-19 patients compared to clinically diagnosed individuals.
{"title":"Do Levels of the Platelet Activation Markers sCD40 L and SCUBE 1 Differ between Laboratory-Confirmed and Clinically Diagnosed COVID-19 Patients?","authors":"Özkan G, Bayrakçi N, Mutlu Lc, Erdem I, Tuna N, D. m., Yildirim I, Erdal B, çelikkol A, Y. a, Güzel S","doi":"10.26420/thrombhaemostres.2022.1084","DOIUrl":"https://doi.org/10.26420/thrombhaemostres.2022.1084","url":null,"abstract":"Aim: Thromboembolic complications are an important cause of mortality and morbidity in coronavirus disease 2019 (COVID-19) patients. The purpose of this study was to compare levels of the platelet activation markers soluble CD40 ligand (sCD 40L) and signal peptide-CUB-EGF domain-containing protein 1 (SCUBE 1) and hematological parameters between laboratory-confirmed and clinically diagnosed COVID-19 patients. No previous studies have investigated levels of these markers in laboratory-confirmed and clinically diagnosed COVID-19 patients. Material and Method: Fifty-one laboratory-confirmed and clinically diagnosed COVID-19 patients with no exclusion criteria were enrolled in the study. Blood specimens were collected for SCUBE1, sCD40 L, and hematological and biochemical parameter measurement. These parameters from laboratoryconfirmed and clinically diagnosed COVID-19 patients were then compared. Results: SCUBE1 and sCD40L levels were significantly higher in the laboratory-confirmed group compared to the clinically diagnosed group (p<0.05 and p =0.005, respectively). Time elapsing between onset of symptoms and presentation to hospital was significantly shorter in the laboratory-confirmed group, while rates of contact with COVID-19 patients were significantly higher (p <0.001 and p <0.005, respectively). SCUBE 1 levels were significantly negatively correlated with ferritin and C-reactive protein (CRP) (p< 0.05, r= - 0.322 and p< 0.05, r= - 0.351, respectively). Conclusion: This study shows, for the first time in the literature, that levels of the platelet activation markers SCUBE1 and sCD40L are significantly higher in laboratory-confirmed COVID-19 patients compared to clinically diagnosed individuals.","PeriodicalId":246370,"journal":{"name":"Thrombosis & Haemostasis: Research","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129450179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-29DOI: 10.26420/thrombhaemostres.2022.1083
Zheng X, Liang S, W. D, Lin W, Zhang J, Y. M, D. L, Zhang S
VWD is reported as the most common inherited bleeding disorder worldwide, found in approximately 1% population [1-4]. It can be divided into 3 subtypes: type 1, type 2 and type 3, caused by quantitative or qualitative defects of VWF. VWF is a complex plasma protein essential for primary hemostasis and coagulation. VWF helps to bind and stabilize blood clotting FVIII from rapid breakdown within the blood stream. Any defect in VWF can also cause reduction of FVIII levels [5]. Type 3 VWD is the rarest and most severe type due to virtual absence of VWF and very low levels of FVIII, another protein involved in blood clotting. Hemophilia A is another type of genetic bleeding disorder characterized by deficiency in clotting FVIII, usually affecting males. Type 3 VWD can be difficult to diagnose due to its rarity. Symptoms, hemostatic challenge and bleeding history may become more apparent with increasing age. Since type 3 VWD also exhibits very low levels of FVIII resembles hemophilia A and it can be misdiagnosed if based on FVIII levels only.
{"title":"A Novel Mutation Case of Type 3 Von Willebrand Disease Misdiagnosed as Hemophilia A","authors":"Zheng X, Liang S, W. D, Lin W, Zhang J, Y. M, D. L, Zhang S","doi":"10.26420/thrombhaemostres.2022.1083","DOIUrl":"https://doi.org/10.26420/thrombhaemostres.2022.1083","url":null,"abstract":"VWD is reported as the most common inherited bleeding disorder worldwide, found in approximately 1% population [1-4]. It can be divided into 3 subtypes: type 1, type 2 and type 3, caused by quantitative or qualitative defects of VWF. VWF is a complex plasma protein essential for primary hemostasis and coagulation. VWF helps to bind and stabilize blood clotting FVIII from rapid breakdown within the blood stream. Any defect in VWF can also cause reduction of FVIII levels [5]. Type 3 VWD is the rarest and most severe type due to virtual absence of VWF and very low levels of FVIII, another protein involved in blood clotting. Hemophilia A is another type of genetic bleeding disorder characterized by deficiency in clotting FVIII, usually affecting males. Type 3 VWD can be difficult to diagnose due to its rarity. Symptoms, hemostatic challenge and bleeding history may become more apparent with increasing age. Since type 3 VWD also exhibits very low levels of FVIII resembles hemophilia A and it can be misdiagnosed if based on FVIII levels only.","PeriodicalId":246370,"journal":{"name":"Thrombosis & Haemostasis: Research","volume":"31 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114960960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-20DOI: 10.26420/thrombhaemostres.2022.1082
P. M, Machailo Jt, P. V, Lakha A, Waja Mf
Background: Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of Non-Hodgkin lymphoma (NHL). DLBCL is a heterogenous disease and is the most common subtype of NHL occurring in Human Immunodeficiency Virus (HIV) seropositive individuals. Aim: The aim of the study was to review the clinical profile as well as the outcome of adult patients presenting with DLBCL, to a tertiary public sector hospital (Chris Hani Baragwanath Academic Hospital – CHBAH) in Soweto, Johannesburg, South Africa. Patients and Methods: The study entailed a retrospective review of 139 evaluable patients with DLBCL, over a 5 year period. Results: Of the 139 patients reviewed, there were 73 females (53%) and 66 males (47%), with a female: male ratio of 1.1:1. The median age of the patients was 41 years (14-85). Common presenting features included advanced stage disease (83%), constitutional or ‘B’ symptoms (74%), extra-nodal disease (73%) and lymphadenopathy (64%). 81% of the patients were HIV seropositive. The median overall survival was 24 months. Conclusion: DLBCL accounted for 35% of all the patients with NHL during the study period. HIV seropositivity, together with other factors such as significant delays in referral of the patients, late presentations with advanced stage disease, and comorbidities such as Tuberculosis, impacted negatively on the prognosis and the outcome of the patients with DLBCL. Despite the use of Combination Antiretroviral Therapy (cART), appropriate supportive care and specific modalities of treatment, DLBCL continues to pose a challenge in our clinical setting.
{"title":"Diffuse Large B-cell Lymphoma in Adults at Chris Hani Baragwanath Academic Hospital","authors":"P. M, Machailo Jt, P. V, Lakha A, Waja Mf","doi":"10.26420/thrombhaemostres.2022.1082","DOIUrl":"https://doi.org/10.26420/thrombhaemostres.2022.1082","url":null,"abstract":"Background: Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of Non-Hodgkin lymphoma (NHL). DLBCL is a heterogenous disease and is the most common subtype of NHL occurring in Human Immunodeficiency Virus (HIV) seropositive individuals. Aim: The aim of the study was to review the clinical profile as well as the outcome of adult patients presenting with DLBCL, to a tertiary public sector hospital (Chris Hani Baragwanath Academic Hospital – CHBAH) in Soweto, Johannesburg, South Africa. Patients and Methods: The study entailed a retrospective review of 139 evaluable patients with DLBCL, over a 5 year period. Results: Of the 139 patients reviewed, there were 73 females (53%) and 66 males (47%), with a female: male ratio of 1.1:1. The median age of the patients was 41 years (14-85). Common presenting features included advanced stage disease (83%), constitutional or ‘B’ symptoms (74%), extra-nodal disease (73%) and lymphadenopathy (64%). 81% of the patients were HIV seropositive. The median overall survival was 24 months. Conclusion: DLBCL accounted for 35% of all the patients with NHL during the study period. HIV seropositivity, together with other factors such as significant delays in referral of the patients, late presentations with advanced stage disease, and comorbidities such as Tuberculosis, impacted negatively on the prognosis and the outcome of the patients with DLBCL. Despite the use of Combination Antiretroviral Therapy (cART), appropriate supportive care and specific modalities of treatment, DLBCL continues to pose a challenge in our clinical setting.","PeriodicalId":246370,"journal":{"name":"Thrombosis & Haemostasis: Research","volume":"276 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125844634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-30DOI: 10.26420/thrombhaemostres.2022.1081
Vangenechten I, Gadisseur A
Von Willebrand Disease (VWD), as the most common inherited bleeding disorder, is a widely misdiagnosed disease due to several diagnostic pitfalls. At the heart of this challenge lies the complexity and heterogeneity of VWF, significant (pre-) analytic issues, limited access to a comprehensive repertoire of laboratory assays, inter-individual variations, lack of expertise and complex interpretation of results. Next to a personal and family bleeding history, an array of clinical laboratory tests is required because no single test reflects both quantity and quality of VWF. The assays measure different VWF properties and may be affected by (pre-) analytic variables possibly leading to inaccurate interpretation. Therefore, a laboratory investigation and diagnosis according to a standard algorithm, and repetitive testing, are essential for accurate diagnosis which is illustrated in detail in this review.
{"title":"Laboratory Diagnosis and Classification of Von Willebrand Disease: A Review","authors":"Vangenechten I, Gadisseur A","doi":"10.26420/thrombhaemostres.2022.1081","DOIUrl":"https://doi.org/10.26420/thrombhaemostres.2022.1081","url":null,"abstract":"Von Willebrand Disease (VWD), as the most common inherited bleeding disorder, is a widely misdiagnosed disease due to several diagnostic pitfalls. At the heart of this challenge lies the complexity and heterogeneity of VWF, significant (pre-) analytic issues, limited access to a comprehensive repertoire of laboratory assays, inter-individual variations, lack of expertise and complex interpretation of results. Next to a personal and family bleeding history, an array of clinical laboratory tests is required because no single test reflects both quantity and quality of VWF. The assays measure different VWF properties and may be affected by (pre-) analytic variables possibly leading to inaccurate interpretation. Therefore, a laboratory investigation and diagnosis according to a standard algorithm, and repetitive testing, are essential for accurate diagnosis which is illustrated in detail in this review.","PeriodicalId":246370,"journal":{"name":"Thrombosis & Haemostasis: Research","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115176586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-27DOI: 10.26420/thrombhaemostres.2022.1080
Pournaki M, Kia Sah, Tetik S
Wound healing is a complex domain that needs to solve abundant parameters. Changed protein concentration, pH effect on wound environment, mediators of immune system, and aging process are fight subjects of wound healing. Therefore, in modern approaches to improve of challenges are tending to analytical techniques for lighting dark side. Research of genetic markers, micro RNAs expression or post-translational modifications of proteins was recently evaluated in wound healing. In review article, we focused on some parameters of the healing system which are affected processes of wound healing and some analytical approaches which are using to find connect of the network.
{"title":"Analytical Approaches to Wound Healing Process","authors":"Pournaki M, Kia Sah, Tetik S","doi":"10.26420/thrombhaemostres.2022.1080","DOIUrl":"https://doi.org/10.26420/thrombhaemostres.2022.1080","url":null,"abstract":"Wound healing is a complex domain that needs to solve abundant parameters. Changed protein concentration, pH effect on wound environment, mediators of immune system, and aging process are fight subjects of wound healing. Therefore, in modern approaches to improve of challenges are tending to analytical techniques for lighting dark side. Research of genetic markers, micro RNAs expression or post-translational modifications of proteins was recently evaluated in wound healing. In review article, we focused on some parameters of the healing system which are affected processes of wound healing and some analytical approaches which are using to find connect of the network.","PeriodicalId":246370,"journal":{"name":"Thrombosis & Haemostasis: Research","volume":"65 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120936512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-08-24DOI: 10.26420/thrombhaemostres.2022.1079
Jurzak-Mysliwy N, Kula W, Sobieszek G
In the following case report, we present two clinical cases of patients after valvular intervention and percutaneous occluder implantation into the left atrium. The first patient is a 68-year-old male admitted to the Department of Cardiology because of Non-ST-Elevation Myocardial Infarction (NSTEMI). He had a medical history of paroxysmal atrial fibrillation and implantation of a biological mitral prosthesis due to severe secondary mitral regurgitation. Due to contraindications to the chronic use of anticoagulants, the patient underwent percutaneous closure of the left atrium appendage. The second patient is an 80-year-old man with a history of permanent atrial fibrillation. 8 years ago, the patient underwent percutaneous atrial septal defect type II (ASD II) closure with and the Amplatz occluder. A year later, the patient underwent Coronary Artery Bypass Graft (CABG) and biological mitral valve implantation due to multivessel coronary disease accompanied by severe mitral regurgitation. In both patients, Transthoracic Echocardiogram (TTE) showed massive thrombosis in the left atrium.
{"title":"Is It The Blame of The Occluder? Two Cases of Massive Thrombosis in the Left Atrium in Patients with Bioprosthetic Mitral Valve and the Presence of the Occluder Implanted Percutaneously","authors":"Jurzak-Mysliwy N, Kula W, Sobieszek G","doi":"10.26420/thrombhaemostres.2022.1079","DOIUrl":"https://doi.org/10.26420/thrombhaemostres.2022.1079","url":null,"abstract":"In the following case report, we present two clinical cases of patients after valvular intervention and percutaneous occluder implantation into the left atrium. The first patient is a 68-year-old male admitted to the Department of Cardiology because of Non-ST-Elevation Myocardial Infarction (NSTEMI). He had a medical history of paroxysmal atrial fibrillation and implantation of a biological mitral prosthesis due to severe secondary mitral regurgitation. Due to contraindications to the chronic use of anticoagulants, the patient underwent percutaneous closure of the left atrium appendage. The second patient is an 80-year-old man with a history of permanent atrial fibrillation. 8 years ago, the patient underwent percutaneous atrial septal defect type II (ASD II) closure with and the Amplatz occluder. A year later, the patient underwent Coronary Artery Bypass Graft (CABG) and biological mitral valve implantation due to multivessel coronary disease accompanied by severe mitral regurgitation. In both patients, Transthoracic Echocardiogram (TTE) showed massive thrombosis in the left atrium.","PeriodicalId":246370,"journal":{"name":"Thrombosis & Haemostasis: Research","volume":"44 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116821761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-27DOI: 10.26420/thrombhaemostres.2022.1078
H. R., Javed B, A. M., Khakwani Kzr, Lee Ks, Acharya T
Direct Oral Anticoagulants (DOACs) are widely used for stroke prevention in non-valvular atrial fibrillation, treatment of deep venous thrombosis and pulmonary embolism, and prophylaxis of Venous Thromboembolism (VTE) after hip and knee surgery. Apixaban, a Factor Xa inhibitor, is one of the most efficacious DOACs with some of the lowest bleeding rates. It has therefore been widely adopted into clinical practice. In the recent years, its usefulness has been tested outside traditional clinical paradigms in coronary artery disease, VTE in malignancy, and deep venous thrombosis prophylaxis in acute medical illnesses. Other off label uses include treatment of left ventricular thrombus and transient post procedural use in transcatheter aortic valve replacement and left atrial appendage occlusion device placement. This review systematically evaluates the clinical evidence and knowledge gaps in expanded clinical use of apixaban.
{"title":"The Expanded Role of Apixaban in Cardiovascular Disease Management: A Literature Review","authors":"H. R., Javed B, A. M., Khakwani Kzr, Lee Ks, Acharya T","doi":"10.26420/thrombhaemostres.2022.1078","DOIUrl":"https://doi.org/10.26420/thrombhaemostres.2022.1078","url":null,"abstract":"Direct Oral Anticoagulants (DOACs) are widely used for stroke prevention in non-valvular atrial fibrillation, treatment of deep venous thrombosis and pulmonary embolism, and prophylaxis of Venous Thromboembolism (VTE) after hip and knee surgery. Apixaban, a Factor Xa inhibitor, is one of the most efficacious DOACs with some of the lowest bleeding rates. It has therefore been widely adopted into clinical practice. In the recent years, its usefulness has been tested outside traditional clinical paradigms in coronary artery disease, VTE in malignancy, and deep venous thrombosis prophylaxis in acute medical illnesses. Other off label uses include treatment of left ventricular thrombus and transient post procedural use in transcatheter aortic valve replacement and left atrial appendage occlusion device placement. This review systematically evaluates the clinical evidence and knowledge gaps in expanded clinical use of apixaban.","PeriodicalId":246370,"journal":{"name":"Thrombosis & Haemostasis: Research","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130037966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-26DOI: 10.26420/thrombhaemostres.2022.1077
K. R, M. S., Hallan Ss
Drug resistance has become a main concern in the cancer therapy worldwide. It can be a temporary or permanent potential of an organismto multiply even in the presence of the lethal drug concentration.Generally, multidrug resistance (MDR) is associated with the over-expression of P-glycoprotein(P-gp), resulting in amplified efflux of anticancer drug molecules from cancer cells [1]. Therefore, interrupting the P-gp efflux might be an effective strategy to resolve the MDR in cancer patients. Interestingly, smart nano-sized transporters can deliver the drug cargo at the proposed site and release the drug precisely to elicit desirable therapeutic response. Thanks to their small diameter, large surface area. Now a days, researchers have explored a smart drug delivery system known as polymer lipid hybrid nanoparticles, which are capable to combat various diseases [2,3]. Over expressed ATP-Binding Cassette (ABC) transporters is frequently associated with MDR in cancer treatments. However, no approved anti-cancer drug molecules are available for clinical use in order to reverse MDR by obstructing P-glycoprotein. However, MDR is responsible for the low intracellular drug concentrations ultimately reduce the cytotoxicity of a broad spectrum of antitumor drugs including anthracyclines (e.g. DOX), vinca alkaloids (e.g. vincristine), podophyllotoxins (e.g. etoposide) and taxanes (e.g. taxol) [4].
{"title":"Liposomes: A Promising Strategy to Treat Multidrug Resistance in Cancers","authors":"K. R, M. S., Hallan Ss","doi":"10.26420/thrombhaemostres.2022.1077","DOIUrl":"https://doi.org/10.26420/thrombhaemostres.2022.1077","url":null,"abstract":"Drug resistance has become a main concern in the cancer therapy worldwide. It can be a temporary or permanent potential of an organismto multiply even in the presence of the lethal drug concentration.Generally, multidrug resistance (MDR) is associated with the over-expression of P-glycoprotein(P-gp), resulting in amplified efflux of anticancer drug molecules from cancer cells [1]. Therefore, interrupting the P-gp efflux might be an effective strategy to resolve the MDR in cancer patients. Interestingly, smart nano-sized transporters can deliver the drug cargo at the proposed site and release the drug precisely to elicit desirable therapeutic response. Thanks to their small diameter, large surface area. Now a days, researchers have explored a smart drug delivery system known as polymer lipid hybrid nanoparticles, which are capable to combat various diseases [2,3]. Over expressed ATP-Binding Cassette (ABC) transporters is frequently associated with MDR in cancer treatments. However, no approved anti-cancer drug molecules are available for clinical use in order to reverse MDR by obstructing P-glycoprotein. However, MDR is responsible for the low intracellular drug concentrations ultimately reduce the cytotoxicity of a broad spectrum of antitumor drugs including anthracyclines (e.g. DOX), vinca alkaloids (e.g. vincristine), podophyllotoxins (e.g. etoposide) and taxanes (e.g. taxol) [4].","PeriodicalId":246370,"journal":{"name":"Thrombosis & Haemostasis: Research","volume":"72 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132875254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-18DOI: 10.26420/thrombhaemostres.2022.1076
Goller Julia, Ratayczak Mark, Dahlem Markus, B. M., Ballmann Clemens, Middeldorf Thomas, Lengfeld Hendrik, Ess Gabriele, Bill Oliver, Tekin G, Schmitz Volker
The worldwide spread of SARS-CoV-2 profoundly affected almost all aspects of public life and challenged international and national health institutions of all different medical care levels including Europe up from the very beginning in 2020 until today. Public and press perception might have been weighed somehow towards third level health care providers offering treatment options like ECMO therapy for Covid-19 patients with the worst disease course, the majority of patients who needed hospital care were treated in hospitals of the first level. These hospitals provided about 50% of intensive care treatments in the federal state of Rhineland Palatinate (RLP) in Germany, too [1]. According to the Destatis [2] about 71000 additional deaths were registered in Germany during the first 12 months (02/2020 – 02/2021) of pandemic of which about 50000 could be attributed to Covid-19 as given in the medical death reports. However, only few data has been published on the concrete disease course and patient´s outcome on the scale of a single treatment site. Thus, this analysis provides routine data on patient´s characteristics, treatment modalities and outcome in a single first level hospital in RLP during the first three Covid-19 surges during 03/2020 – 07/2021.
{"title":"Disease Course and Patient’s Characteristics in a Regional First Level Hospital in Western-Germany During the First Three Covid-19 Surges from March 2020 to July 2021","authors":"Goller Julia, Ratayczak Mark, Dahlem Markus, B. M., Ballmann Clemens, Middeldorf Thomas, Lengfeld Hendrik, Ess Gabriele, Bill Oliver, Tekin G, Schmitz Volker","doi":"10.26420/thrombhaemostres.2022.1076","DOIUrl":"https://doi.org/10.26420/thrombhaemostres.2022.1076","url":null,"abstract":"The worldwide spread of SARS-CoV-2 profoundly affected almost all aspects of public life and challenged international and national health institutions of all different medical care levels including Europe up from the very beginning in 2020 until today. Public and press perception might have been weighed somehow towards third level health care providers offering treatment options like ECMO therapy for Covid-19 patients with the worst disease course, the majority of patients who needed hospital care were treated in hospitals of the first level. These hospitals provided about 50% of intensive care treatments in the federal state of Rhineland Palatinate (RLP) in Germany, too [1]. According to the Destatis [2] about 71000 additional deaths were registered in Germany during the first 12 months (02/2020 – 02/2021) of pandemic of which about 50000 could be attributed to Covid-19 as given in the medical death reports. However, only few data has been published on the concrete disease course and patient´s outcome on the scale of a single treatment site. Thus, this analysis provides routine data on patient´s characteristics, treatment modalities and outcome in a single first level hospital in RLP during the first three Covid-19 surges during 03/2020 – 07/2021.","PeriodicalId":246370,"journal":{"name":"Thrombosis & Haemostasis: Research","volume":"56 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121220330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-07-12DOI: 10.26420/thrombhaemostres.2022.1075
Muntadhar Al, Moosawi Md
Blood management in liver transplant surgeries can be challenging. In this article I will address some of the strenuous challenges related to blood management in this patient population and discuss the use of rotational thromboelastometry (ROTEM) to mitigate these challenges. It is well known that patients with liver disease have a rebalanced hemostasis due to the impaired synthesis of both the coagulation factors and pro-coagulant factors. Interestingly, some studies demonstrated an increased endogenous thrombin potential (ETP) in patients with liver cirrhosis [1]. Hence, it is now well known that this group of patients requires special attention when it comes to blood management.
{"title":"The Use of ROTEM in Liver Transplant Surgeries: A Luxurious Option or a Necessity?!","authors":"Muntadhar Al, Moosawi Md","doi":"10.26420/thrombhaemostres.2022.1075","DOIUrl":"https://doi.org/10.26420/thrombhaemostres.2022.1075","url":null,"abstract":"Blood management in liver transplant surgeries can be challenging. In this article I will address some of the strenuous challenges related to blood management in this patient population and discuss the use of rotational thromboelastometry (ROTEM) to mitigate these challenges. It is well known that patients with liver disease have a rebalanced hemostasis due to the impaired synthesis of both the coagulation factors and pro-coagulant factors. Interestingly, some studies demonstrated an increased endogenous thrombin potential (ETP) in patients with liver cirrhosis [1]. Hence, it is now well known that this group of patients requires special attention when it comes to blood management.","PeriodicalId":246370,"journal":{"name":"Thrombosis & Haemostasis: Research","volume":"77 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116762094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：